Biogen Inc (NASDAQ: BIIB)’s stock price has plunge by 5.65relation to previous closing price of 114.05. Nevertheless, the company has seen a -8.25% plunge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-04-09 that Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen’s $7.22 per share buyout offer signals confidence in Sage’s commercial potential and drug pipeline, despite the market’s current undervaluation. Sage’s Zuranolone shows strong market traction in PPD, with significant insurance coverage and increasing prescriptions, indicating future growth potential.
Is It Worth Investing in Biogen Inc (NASDAQ: BIIB) Right Now?
The price-to-earnings ratio for Biogen Inc (NASDAQ: BIIB) is above average at 10.78x, Company’s 36-month beta value is 0.23.Analysts have differing opinions on the stock, with 13 analysts rating it as a “buy,” 6 as “overweight,” 18 as “hold,” and 0 as “sell.”
The public float for BIIB is 145.62M, and currently, short sellers hold a 2.27% ratio of that floaft. The average trading volume of BIIB on April 10, 2025 was 1.66M shares.
BIIB’s Market Performance
BIIB’s stock has seen a -8.25% decrease for the week, with a -16.13% drop in the past month and a -21.33% fall in the past quarter. The volatility ratio for the week is 6.24%, and the volatility levels for the past 30 days are at 3.50% for Biogen Inc The simple moving average for the last 20 days is -10.72% for BIIB stock, with a simple moving average of -30.69% for the last 200 days.
Analysts’ Opinion of BIIB
Bernstein, on the other hand, stated in their research note that they expect to see BIIB reach a price target of $160. The rating they have provided for BIIB stocks is “Mkt Perform” according to the report published on February 11th, 2025.
Piper Sandler gave a rating of “Neutral” to BIIB, setting the target price at $138 in the report published on January 02nd of the current year.
BIIB Trading at -13.39% from the 50-Day Moving Average
After a stumble in the market that brought BIIB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.37% of loss for the given period.
Volatility was left at 3.50%, however, over the last 30 days, the volatility rate increased by 6.24%, as shares sank -14.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.18% lower at present.
During the last 5 trading sessions, BIIB fell by -8.25%, which changed the moving average for the period of 200-days by -46.21% in comparison to the 20-day moving average, which settled at $134.96. In addition, Biogen Inc saw -21.21% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BIIB starting from SHERWIN STEPHEN A, who sale 8,760 shares at the price of $150.02 back on Mar 07 ’25. After this action, SHERWIN STEPHEN A now owns 11,318 shares of Biogen Inc, valued at $1,314,142 using the latest closing price.
STEPHEN A SHERWIN, the Director of Biogen Inc, proposed sale 8,760 shares at $147.37 during a trade that took place back on Mar 07 ’25, which means that STEPHEN A SHERWIN is holding shares at $1,290,961 based on the most recent closing price.
Stock Fundamentals for BIIB
Current profitability levels for the company are sitting at:
- 0.31 for the present operating margin
- 0.79 for the gross margin
The net margin for Biogen Inc stands at 0.17. The total capital return value is set at 0.13. Equity return is now at value 10.36, with 5.95 for asset returns.
Based on Biogen Inc (BIIB), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at 0.59. The debt to equity ratio resting at 0.28. The interest coverage ratio of the stock is 15.43.
When we switch over and look at the enterprise to sales, we see a ratio of 2.13. The receivables turnover for the company is 6.74for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.35.
Conclusion
In a nutshell, Biogen Inc (BIIB) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
